Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPRESS trial for prophylactic suppression of frequent premature ventricular complexes in asymptomatic patients
2024-516372-14-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of flecainide, amiodarone, verapamil, nebivolol, bisoprolol and 3 more in Premature ventricular complexes (PVC) and premature ventricular complex-induced cardiomyopathy (PVC-CM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jan 2025; status: authorised.
02
Drugs
flecainideamiodaroneverapamilnebivololbisoprolol
03
Conditions
Premature ventricular complexes (PVC)premature ventricular complex-induced cardiomyopathy (PVC-CM)
Beyond the preview
Go deeper on 2024-516372-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516372-14-00.